Value_Investor
5 years ago
Who dumped 1,125,000 shares at 0.0002? Why? I bet it must be because of the current Giant AS size --- 10B or 10,000,000,000 shares!
Will it further crash to its All-Time-Low 0.0001 due to the planned Huge R/S? The current price 0.0006 is 500%-Higher than its Bottom 0.0001!
TNGNQ had approximately $31.6 million of principal and accrued but unpaid interest remains outstanding under the promissory notes governed by such agreements! Will the company dilute 10B shares at $0.0001 to raise $1M cash to pay off its partial Giant debts?
Anyway TNGNQ has Giant Negative Book Value --- -$2.0719 per share v.s. its peer LIQDQ has Giant Positive BV --- $0.1864 per share. TNGNQ has 10B shares Giant AS v.s. LIQDQ only has 200M or 0.2B shares Tiny AS!
Calvin Hobbes
8 years ago
TNGNQ Security Details
Share Structure
Market Value1 $69,578 a/o Nov 08, 2016
Authorized Shares Not Available
Outstanding Shares 36,620,124 a/o Nov 10, 2014
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
did not realize SS was so low on this one.
Fern Wood
10 years ago
As part of the Termination Plan (as defined and described below), the Company plans to terminate the employment of Mr. Miclot, Mr. Davis and Dr. Bertram effective December 5, 2014, December 23, 2014 and December 5, 2014, respectively.
On December 1, 2014, the Companyโs Board of Directors (the โBoardโ) approved a plan of termination (the โTermination Planโ) that will result in a workforce reduction of all of the Companyโs 29 employees (the โTerminated Employeesโ), including Mr. Miclot, Mr. Davis and Dr. Bertram, by the end of 2014. The Terminated Employees serve in research, development, financial and administrative roles.
ALERTS100%to10000%GAIN
10 years ago
TNGN~~Tengion Retains Jefferies to Explore Strategic Options for the Company
WINSTON-SALEM, N.C., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that the Company, with the support of its Board of Directors, is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions.
"We believe this decision increases our ability to realize the value of our Organ Regeneration Platform and we remain committed to maximizing value for our stakeholders," commented John L. Miclot, President and Chief Executive Officer of Tengion.
The Company does not intend to comment further on this process unless and until a definitive agreement has been reached.
About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platformโข to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. The Company is currently conducting Phase 1 clinical trials in Sweden and the United States for its Neo-Kidney Augment, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. A Phase 1 trial for the Company's Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal, has completed enrollment.